268 related articles for article (PubMed ID: 37745842)
1.
Mroczkowska-Bękarciak A; Wróbel T
Front Genet; 2023; 14():1241912. PubMed ID: 37745842
[TBL] [Abstract][Full Text] [Related]
2. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of
Abbou N; Piazzola P; Gabert J; Ernest V; Arcani R; Couderc AL; Tichadou A; Roche P; Farnault L; Colle J; Ouafik L; Morange P; Costello R; Venton G
Cells; 2022 Dec; 12(1):. PubMed ID: 36611899
[No Abstract] [Full Text] [Related]
3. [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases].
Li ZL; Gao L; Zhang H; Zhang CX; Chen YR; Huang FZ; Gong M; Gao YY; Tang Y; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1122-1128. PubMed ID: 30111418
[TBL] [Abstract][Full Text] [Related]
4. Functional Consequences of Mutations in Myeloproliferative Neoplasms.
Constantinescu SN; Vainchenker W; Levy G; Papadopoulos N
Hemasphere; 2021 Jun; 5(6):e578. PubMed ID: 34095761
[TBL] [Abstract][Full Text] [Related]
5. Distinctive Attributes of Indian Patients With Classical BCR::ABL1 Negative Myeloproliferative Neoplasms: Unified Clinical and Laboratory Data.
Singh S; Singh J; Mehta A; Sharma R; Joshi K; Jain K; Paul D; Oberoi G; Jindal N; Dhillon B; Narang V
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):360-369.e1. PubMed ID: 36849307
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloproliferative neoplasms with concomitant
Zanelli M; Fragliasso V; Loscocco GG; Sanguedolce F; Broggi G; Zizzo M; Palicelli A; Ricci S; Ambrogi E; Martino G; Aversa S; Coppa F; Gentile P; Gozzi F; Caltabiano R; Koufopoulos N; Asaturova A; Cimino L; Cavazza A; Orcioni GF; Ascani S
Front Cell Dev Biol; 2024; 12():1391078. PubMed ID: 38596359
[TBL] [Abstract][Full Text] [Related]
7. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
8. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
9. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
12. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
13. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
Khodier M; Gadó K
Physiol Int; 2023 Sep; 110(3):227-250. PubMed ID: 37651280
[TBL] [Abstract][Full Text] [Related]
14. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
16. Co-occurrence of
Zanelli M; Bisagni A; Sanguedolce F; Broggi G; Fragliasso V; Zizzo M; Palicelli A; Martino G; Cresta C; Caprera C; Corsi M; Gentile P; Gozzi F; Trombetta D; Parente P; Caltabiano R; Koufopoulos N; Cimino L; Cavazza A; Fraternali Orcioni G; Ascani S
Front Oncol; 2023; 13():1329298. PubMed ID: 38282677
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of the clinical features of 172 patients with
Lin X; Huang H; Chen P
Mol Cytogenet; 2020; 13():8. PubMed ID: 32095159
[TBL] [Abstract][Full Text] [Related]
18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
20. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
